Cytokinetics presents positive Myqorzo results, seeks broader heart disease indication

At the European Society of Cardiology meeting, Cytokinetics unveiled detailed data supporting Myqorzo for a specific heart muscle condition. The company expects to pursue an expanded approval next year, which could double the drug's addressable patient population. The findings were highlighted as a key step toward widening the therapy's use.